Health · Medical Research · 16 hrs ago
MD Anderson and P-Cure partner to study proton and helium cancer therapy
MD Anderson and P-Cure have formed a partnership to develop and evaluate particle-based cancer treatment.
The work involves the University of Texas MD Anderson Cancer Center in the United States and P-Cure, a company with an FDA-cleared compact proton therapy platform.
The partnership will first assess P-Cure’s proton system, which delivers treatment with patients sitting upright.
Particle therapy aims to target tumors while limiting radiation exposure to nearby healthy tissue.
Researchers will also study helium ions, which may offer more precise radiation delivery and stronger biological effects than proton therapy.
The long-term goal is one system that can deliver protons or helium ions, allowing doctors to choose treatment based on a patient’s disease.
The collaboration will begin with clinical evaluation of the proton platform, then pursue preclinical and clinical studies of helium therapy to build evidence for possible adoption and regulatory approval.
If the approach succeeds, it could become the first helium particle system in North America.
The University of Texas MD Anderson Cancer Center and P-Cure Ltd. announced a strategic alliance to study proton and helium ion cancer therapy.
The partners aim to develop and clinically validate a compact upright system that could deliver either type of therapy.
The initial focus will be evaluating the clinical value, patient benefits and operational advantages of P-Cure’s proton therapy platform.
Future preclinical and clinical work will investigate helium ions and build evidence for possible clinical adoption.
If successful, the platform would be the first helium particle system in North America.
- Who
- The University of Texas MD Anderson Cancer Center and P-Cure Ltd.
- What
- They announced an alliance to study a particle therapy platform for proton and helium ion treatment.
- When
- November 9, 2026, the article’s publication date.
- Where
- Not stated.
- Why
- To evaluate the therapies’ clinical potential and build evidence for possible future use.
This story does not have two clearly opposing sides.
The alliance will focus on clinical value, patient benefits and operational advantages of P-Cure’s compact upright proton therapy solution.
The partners plan preclinical and clinical programs to investigate helium ion therapy and establish its therapeutic potential.
- Partners
- The University of Texas MD Anderson Cancer Center and P-Cure Ltd.
- Therapy types
- Proton and helium ion
- Platform
- Compact upright treatment system
- Initial focus
- Clinical evaluation of P-Cure’s proton therapy solution
- Potential first
- First helium particle system in North America if successful
What people are saying
As clinicians and researchers, we are committed to exploring technologies that have the potential to improve outcomes and expand access to advanced cancer care.
Helium therapy has the potential to become the next major advancement in particle therapy.